songpku's pharmacogenetics [70 articles] Export

Recent papers added to songpku's library classified by the tag pharmacogenetics. You can also see everyone's pharmacogenetics.

Hide details

	Genetic polymorphisms in estrogen-metabolizing genes and breast cancer survival. [My Copy] Pharmacogenetics and genomics, Vol. 17, No. 5. (May 2007), pp. 331-338. by Ji-Rong R. Long, Qiuyin Cai, Xiao-Ou O. Shu, Hui Cai, Yu-Tang T. Gao, Wei Zheng posted to polymorphism pharmacogenetics cyp1a2 cyp1a1 cancer breast by songpku on 2009-11-24 04:53:38 as along with 1 person and 1 group carore Asian Pharmacogenetics Library
	CYP1A1 polymorphisms modify overall survival in acute myeloid leukemia patients. [My Copy] Leukemia & lymphoma, Vol. 48, No. 6. (June 2007), pp. 1211-1215. by Luís Arthur Flores A. Pelloso, Ismael Dale Cotrim Guerreiro D. Da Silva, Naiara Côrrea Nogueira C. De Souza, Mihoko Yamamoto, Carlos Alberto Oliveira A. Botelho, Maria De Lourdes Ferrari d. e. . L. Chauffaille posted to survival polymorphism pharmacogenetics leukemia cyp1a1 by songpku on 2009-11-24 04:46:09 as
	Nitric Oxide Synthase Variants and Disease-Free Survival among Treated and Untreated Breast Cancer Patients in a Southwest Oncology Group Clinical Trial [My Copy] Clinical Cancer Research, Vol. 15, No. 16. (15 August 2009), pp. 5258-5266. by Ji-Yeob Choi, William E. Barlow, Kathy S. Albain, et al.Chi-Chen Hong, Javier G. Blanco, Robert B. Livingston, Warren Davis, James M. Rae, I-Tien Yeh, Laura F. Hutchins, Peter M. Ravdin, Silvana Martino, Alan P. Lyss, C. Kent Osborne, Martin D. Abeloff, Daniel F. Hayes, Christine B. Ambrosone posted to survival pharmacogenetics nos cancer breast ambrosone by songpku on 2009-11-24 03:28:41 as along with 1 person misonneh
	Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. [My Copy] Pharmacogenomics, Vol. 5, No. 7. (October 2004), pp. 895-931. by Joseph F. Solus, Brenda J. Arietta, James R. Harris, et al.David P. Sexton, John Q. Steward, Chara McMunn, Patrick Ihrie, Janelle M. Mehall, Todd L. Edwards, Elliott P. Dawson posted to variant racial polymorphism phase pharmacogenetics i genetic difference cyp by songpku on 2009-11-23 21:22:40 as along with 5 people and 1 group YinJinJang jjing03 kjkj0001 parkjs80 carore Asian Pharmacogenetics Library
	Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms [My Copy] Clinical Pharmacology & Therapeutics, Vol. 79, No. 6. (01 June 2006), pp. 570-580. by A. Tran, V. Jullien, J. Alexandre, et al.E. Rey, F. Rabillon, V. Girre, V. Dieras, G. Pons, F. Goldwasser, J. M. Treluyer posted to variant taxane pharmacogenetics genetic cancer breast by songpku on 2009-11-23 00:14:38 as
	Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen [My Copy] JAMA, Vol. 302, No. 13. (7 October 2009), pp. 1429-1436. by Werner Schroth, Matthew P. Goetz, Ute Hamann, et al.Peter A. Fasching, Marcus Schmidt, Stefan Winter, Peter Fritz, Wolfgang Simon, Vera J. Suman, Matthew M. Ames, Stephanie L. Safgren, Mary J. Kuffel, Hans U. Ulmer, Julia Bolander, Reiner Strick, Matthias W. Beckmann, Heinz Koelbl, Richard M. Weinshilboum, James N. Ingle, Michel Eichelbaum, Matthias Schwab, Hiltrud Brauch posted to tamoxifen polymorphism pharmacogenetics cyp2d6 cancer breast by songpku on 2009-11-22 22:54:50 as along with 2 people misonneh merpublic
	Cancer Survival and Copy Number Variations [My Copy] posted to survival pharmacogenetics cnv cancer by songpku on 2009-11-08 02:22:44 as
	Human genome variation and pharmacogenetics [My Copy] Human Mutation, Vol. 29, No. 4. (2008), pp. 453-455. by Bruce Gottlieb posted to variation pharmacogenetics genome cnv cancer by songpku on 2009-11-08 02:17:31 as
	Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients [My Copy] Breast Cancer Research and Treatment, Vol. 91, No. 3. (28 June 2005), pp. 249-258. by Susan A. Nowell, Jiyoung Ahn, James M. Rae, et al.Joshua O. Scheys, Andrew Trovato, Carol Sweeney, Stewart L. MacLeod, Fred F. Kadlubar, Christine B. Ambrosone posted to tamoxifen pharmacogenetics cyp2d6 cancer breast by songpku on 2009-10-19 21:58:35 as along with 2 people Mi-Seon frohike
	Genetic susceptibility of term pregnant women to oxidative damage [My Copy] Toxicology Letters, Vol. 129, No. 3. (28 March 2002), pp. 255-262. by Y. Hong posted to sod2 phenotype pharmacogenetics mnsod by songpku on 2009-10-19 21:53:30 as
	Genotype-activity relationship for Mn-superoxide dismutase, glutathione peroxidase 1 and catalase in humans. [My Copy] Pharmacogenetics and genomics, Vol. 16, No. 4. (April 2006), pp. 279-286. by Maria Bastaki, Karen Huen, Paolo Manzanillo, et al.Neha Chande, Connie Chen, John R. Balmes, Ira B. Tager, Nina Holland posted to sod pharmacogenetics mnsod by songpku on 2009-10-19 21:50:25 as
	Myeloperoxidase Genotypes and Enhanced Efficacy of Chemotherapy for Early-Stage Breast Cancer in SWOG-8897. [My Copy] Journal of clinical oncology : official journal of the American Society of Clinical Oncology (14 September 2009) by Christine B. Ambrosone, William E. Barlow, Wanda Reynolds, et al.Robert B. Livingston, I-Tien T. Yeh, Ji-Yeob Y. Choi, Warren Davis, James M. Rae, Li Tang, Laura R. Hutchins, Peter M. Ravdin, Silvana Martino, C. Kent Osborne, Alan P. Lyss, Daniel F. Hayes, Kathy S. Albain posted to pharmacogenetics mpo cancer breast ambrosone by songpku on 2009-10-18 18:10:53 as
	Pharmacogenomics: translating functional genomics into rational therapeutics. [My Copy] Science (New York, N.Y.), Vol. 286, No. 5439. (15 October 1999), pp. 487-491. by W. E. Evans, M. V. Relling posted to review pharmacogenetics cancer by songpku on 2009-10-18 16:35:00 as
	Modulation of cytochrome P450 activity: implications for cancer therapy. [My Copy] The lancet oncology, Vol. 6, No. 10. (October 2005), pp. 780-789. by Charity D. Scripture, Alex Sparreboom, William D. Figg posted to therapy review pharmacogenetics p450 cancer by songpku on 2009-10-18 16:25:39 as
	Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients [My Copy] The Pharmacogenomics Journal, Vol. aop, No. current. (29 September 2009) by A. V. Khrunin, A. Moisseev, V. Gorbunova, S. Limborska posted to polymorphism pharmacogenetics ovarian metabolism gstp1 gsta1 cancer by songpku on 2009-10-11 04:40:06 as along with 1 person poojamaj
	Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. [My Copy] Cancer, Vol. 103, No. 1. (1 January 2005), pp. 52-58. by Gong Yang, Xiao-Ou O. Shu, Zhi-Xian X. Ruan, et al.Qiu-Yin Y. Cai, Fan Jin, Yu-Tang T. Gao, Wei Zheng posted to survival polymorphism pharmacogenetics metabolism gstp1 cancer breast by songpku on 2009-10-11 04:03:03 as along with 1 person Mi-Seon
	Association between Survival after Treatment for Breast Cancer and Glutathione S-Transferase P1 Ile105Val Polymorphism [My Copy] Cancer Res, Vol. 60, No. 20. (1 October 2000), pp. 5621-5624. by Carol Sweeney, Gail Y. McClure, Manal Y. Fares, et al.Angie Stone, Brian F. Coles, Patricia A. Thompson, Soheila Korourian, Laura F. Hutchins, Fred F. Kadlubar, Christine B. Ambrosone posted to pharmacogenetics gstp1 cancer breast by songpku on 2009-10-11 03:03:35 as
	Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer [My Copy] Breast Cancer Research and Treatment, Vol. 111, No. 1. (1 September 2008), pp. 93-101. by Mary Bewick, Michael Conlon, Robert Lafrenie posted to sod polymorphism pharmacogenetics mnsod cancer breast by songpku on 2009-09-30 16:45:38 as
	Pharmacogenetics of cyclophosphamide in patients with hematological malignancies [My Copy] European Journal of Pharmaceutical Sciences, Vol. 27, No. 1. (January 2006), pp. 54-61. by Hanjing Xie, Laimonas Griskevicius, Lars Ståhle, et al.Zuzana Hassan, Ümit Yasar, Anders Rane, Ulrika Broberg, Eva Kimby, Moustapha Hassan posted to polymorphism pharmacogenetics cyp2b6 cyclophosphamide by songpku on 2009-09-18 17:14:50 as
	An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. [My Copy] Cancer treatment reviews, Vol. 35, No. 1. (February 2009), pp. 18-31. by Corine Ekhart, Sjoerd Rodenhuis, Paul H. Smits, Jos H. Beijnen, Alwin D. Huitema posted to pharmacogenetics gsta1 cyp3a4 cyp2b6 cyclophosphamide by songpku on 2009-08-27 19:28:02 as
	Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy. [My Copy] Advanced drug delivery reviews, Vol. 61, No. 5. (20 May 2009), pp. 381-387. by Sharon Marsh, Geoffrey Liu posted to pharmacogenetics gsta1 cyp3a4 cyp2b6 cyclophosphamide by songpku on 2009-08-27 19:26:06 as
	Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. [My Copy] Fertility and sterility (17 April 2009) by H. Irene Su, Mary D. Sammel, Luke Velders, et al.Michelle Horn, Corrie Stankiewicz, Jennifer Matro, Clarisa R. Gracia, Jamie Green, Angela Demichele posted to pharmacogenetics gsta1 cyp3a4 cyp2b6 cyclophosphamide by songpku on 2009-08-27 19:21:58 as
	Glutathione S-transferase (GSTM1, GSTT1 and GSTA1) polymorphisms and outcomes after treatment for acute myeloid leukemia: pharmacogenetics in Southwest Oncology Group (SWOG) clinical trials [My Copy] Leukemia, Vol. 20, No. 12. (28 September 2006), pp. 2169-2171. by J. R. Weiss, K. J. Kopecky, J. Godwin, et al.J. Anderson, C. L. Willman, K. B. Moysich, M. L. Slovak, A. Hoque, C. B. Ambrosone posted to polymorphism pharmacogenetics gsta1 by songpku on 2009-08-27 19:16:04 as
	Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. [My Copy] Pharmacogenetics, Vol. 11, No. 8. (November 2001), pp. 663-669. by B. F. Coles, F. Morel, C. Rauch, et al.W. W. Huber, M. Yang, C. H. Teitel, B. Green, N. P. Lang, F. F. Kadlubar posted to pharmacogenetics gsta1 by songpku on 2009-08-27 18:01:04 as
	The human glutathione transferase alpha locus: genomic organization of the gene cluster and functional characterization of the genetic polymorphism in the hGSTA1 promoter. [My Copy] Pharmacogenetics, Vol. 12, No. 4. (June 2002), pp. 277-286. by Fabrice Morel, Claudine Rauch, Brian Coles, Eric Le Ferrec, André Guillouzo posted to pharmacogenetics gsta1 by songpku on 2009-08-27 18:00:53 as
	Effects of glutathione S-transferase A1 (GSTA1) genotype and potential modifiers on breast cancer risk [My Copy] Carcinogenesis, Vol. 27, No. 9. (1 September 2006), pp. 1876-1882. by Jiyoung Ahn, Marilie D. Gammon, Regina M. Santella, et al.Mia M. Gaudet, Julie A. Britton, Susan L. Teitelbaum, Mary B. Terry, Alfred I. Neugut, Sybil M. Eng, Yuesheng Zhang, Cutberto Garza, Christine B. Ambrosone posted to pharmacogenetics gsta1 cancer breast by songpku on 2009-08-27 18:00:11 as
	Interindividual Differences in Hepatic Expression of CYP3A4: Relationship to Genetic Polymorphism in the 5-Upstream Regulatory Region [My Copy] Biochemical and Biophysical Research Communications (May 1999), pp. 201-205. by A. Westlind, L. Lofberg, N. Tindberg, T. B. Andersson, M. Ingelman-Sundberg posted to pharmacogenetics cyp3a4 cyclophosphamide by songpku on 2009-08-27 17:25:41 as
	Population distribution and effects on drug metabolism of a genetic variant in the 5[prime] promotor region of CYP3A4 [My Copy] Clin Pharmacol Ther, Vol. 66, No. 3. (September 1999), pp. 288-294. by Simon E. Ball, Joann Scatina, John Kao, et al.Geraldine M. Ferron, Richard Fruncillo, Philip Mayer, Ira Weinryb, Marco Guida, Penelope J. Hopkins, Natalie Warner, Jeff Hall posted to pharmacogenetics cyp3a4 cyclophosphamide by songpku on 2009-08-27 17:25:32 as
	Association of CYP3A4 genotype with treatment-related leukemia [My Copy] Proceedings of the National Academy of Sciences of the United States of America, Vol. 95, No. 22. (27 October 1998), pp. 13176-13181. by Carolyn A. Felix, Amy H. Walker, Beverly J. Lange, et al.Terence M. Williams, Naomi J. Winick, Nai-Kong V. Cheung, Brian D. Lovett, Peter C. Nowell, Ian A. Blair, Timothy R. Rebbeck posted to pharmacogenetics cyp3a4 cyclophosphamide by songpku on 2009-08-27 17:25:15 as
	Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. [My Copy] Journal of the National Cancer Institute, Vol. 90, No. 16. (19 August 1998), pp. 1225-1229. by T. R. Rebbeck, J. M. Jaffe, A. H. Walker, A. J. Wein, S. B. Malkowicz posted to pharmacogenetics cyp3a4 cyclophosphamide by songpku on 2009-08-27 17:25:04 as
	Cytochrome P450 3A pharmacogenetics: the road that needs traveled [My Copy] Pharmacogenomics J, Vol. 3, No. 1. (0000), pp. 3-5. by D. A. Flockhart, J. M. Rae posted to pharmacogenetics cyp3a4 cyclophosphamide by songpku on 2009-08-27 17:04:20 as
	Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. [My Copy] Pharmacogenetics and genomics, Vol. 17, No. 6. (June 2007), pp. 431-445. by Miki Nakajima, Sayaka Komagata, Yuto Fujiki, et al.Yoshihiro Kanada, Hiromichi Ebi, Kuniaki Itoh, Hirofumi Mukai, Tsuyoshi Yokoi, Hironobu Minami posted to pharmacogenetics cyp2b6 cyclophosphamide by songpku on 2009-08-27 16:37:26 as
	Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. [My Copy] International journal of cancer. Journal international du cancer, Vol. 103, No. 6. (1 March 2003), pp. 810-814. by Carol Sweeney, Christine B. Ambrosone, Lija Joseph, et al.Angie Stone, Laura F. Hutchins, Fred F. Kadlubar, Brian F. Coles posted to pharmacogenetics gsta1 cyclophosphamide by songpku on 2009-08-27 16:32:45 as
	Associations Between Drug Metabolism Genotype, Chemotherapy Pharmacokinetics, and Overall Survival in Patients With Breast Cancer [My Copy] J Clin Oncol, Vol. 23, No. 25. (1 September 2005), pp. 6117-6125. by William P. Petros, Penelope J. Hopkins, Susan Spruill, et al.Gloria Broadwater, James J. Vredenburgh, O. Michael Colvin, William P. Peters, Roy B. Jones, Jeff Hall, Jeffrey R. Marks posted to pharmacogenetics metabolism enzyme drug cyp3a4 cyp2b6 by songpku on 2009-08-27 16:31:16 as
	Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation [My Copy] Pharmacogenomics J, Vol. 3, No. 1. (0000), pp. 53-61. by H. J. Xie, U. Yasar, S. Lundgren, et al.L. Griskevicius, Y. Terelius, M. Hassan, A. Rane posted to pharmacogenetics cyp2b6 cyclophosphamide by songpku on 2009-08-27 15:59:47 as
	A Single Nucleotide Polymorphism of CYP2B6 Found in Japanese Enhances Catalytic Activity by Autoactivation [My Copy] Biochemical and Biophysical Research Communications, Vol. 281, No. 5. (16 March 2001), pp. 1256-1260. by N. Ariyoshi posted to pharmacogenetics cyp2b6 cyclophosphamide by songpku on 2009-08-27 15:56:46 as
	Pharmacogenetic Pathway Analysis of Docetaxel Elimination [My Copy] Clin Pharmacol Ther, Vol. 85, No. 2. (28 May 2008), pp. 155-163. by S. D. Baker, J. Verweij, G. A. Cusatis, et al.R. H. van Schaik, S. Marsh, S. J. Orwick, R. M. Franke, S. Hu, E. G. Schuetz, V. Lamba, W. A. Messersmith, A. C. Wolff, M. A. Carducci, A. Sparreboom posted to cyp3a4 genotype pharmacogenetics by songpku on 2009-08-10 16:20:20 as
	Human hepatic CYP2B6 developmental expression: The impact of age and genotype [My Copy] Biochemical Pharmacology, Vol. 78, No. 2. (15 July 2009), pp. 184-190. by Edward L. Croom, Jeffrey C. Stevens, Ronald N. Hines, Andrew D. Wallace, Ernest Hodgson posted to cyp2b6 genotype pharmacogenetics polymorphism by songpku on 2009-08-10 16:07:59 as
	Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. [My Copy] Pharmacogenetics and genomics, Vol. 18, No. 11. (November 2008), pp. 955-965. by X. Wu, C. Lu, Y. Ye, et al.J. Chang, H. Yang, J. Lin, J. Gu, W. K. Hong, D. Stewart, M. R. Spitz posted to dna drug genetic metabolism pharmacogenetics polymorphism repair by songpku on 2009-06-24 20:44:29 as
	A Mitochondrial Target Sequence Polymorphism in Manganese Superoxide Dismutase Predicts Inferior Survival in Breast Cancer Patients Treated with Cyclophosphamide [My Copy] Clin Cancer Res, Vol. 15, No. 12. (15 June 2009), pp. 4165-4173. by Sharon A. Glynn, Brenda J. Boersma, Tiffany M. Howe, et al.Hege Edvardsen, Stephanie B. Geisler, Julie E. Goodman, Lisa A. Ridnour, Per E. Lonning, Anne-Lise Borresen-Dale, Bjorn Naume, Vessela N. Kristensen, Stephen J. Chanock, David A. Wink, Stefan Ambs posted to breast cancer cyclophosphamide mnsod pharmacogenetics by songpku on 2009-06-21 18:31:08 as
	Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. [My Copy] Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 25, No. 21. (20 July 2007), pp. 3015-3023. by M. Udler, A. T. Maia, A. Cebrian, et al.C. Brown, D. Greenberg, M. Shah, C. Caldas, A. Dunning, D. Easton, B. Ponder, P. Pharoah posted to breast cancer oxidative pharmacogenetics stress survival by songpku on 2009-06-21 18:29:42 as along with 1 person misonneh
	Polymorphisms in Genes Related to Oxidative Stress (MPO, MnSOD, CAT) and Survival After Treatment for Breast Cancer [My Copy] Cancer Res, Vol. 65, No. 3. (1 February 2005), pp. 1105-1111. by Christine B. Ambrosone, Jiyoung Ahn, Keshav K. Singh, et al.Hamed Rezaishiraz, Helena Furberg, Carol Sweeney, Brian Coles, Andrew Trovato posted to ambrosone breast cancer oxidative pharmacogenetics stress survival by songpku on 2009-06-21 18:25:56 as
	NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. [My Copy] Circulation, Vol. 112, No. 24. (13 December 2005), pp. 3754-3762. by L. Wojnowski, B. Kulle, M. Schirmer, et al.G. Schlüter, A. Schmidt, A. Rosenberger, S. Vonhof, H. Bickeböller, M. R. Toliat, E. K. Suk, M. Tzvetkov, A. Kruger, S. Seifert, M. Kloess, H. Hahn, M. Loeffler, P. Nürnberg, M. Pfreundschuh, L. Trümper, J. Brockmöller, G. Hasenfuss posted to doxorubicin genetic lymphoma mdr nadph pharmacogenetics polymorphism toxicity by songpku on 2009-06-21 05:22:45 as
	Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21 [My Copy] Leukemia, Vol. aop, No. current. by D. Rossi, S. Rasi, S. Franceschetti, et al.D. Capello, A. Castelli, L. De Paoli, A. Ramponi, A. Chiappella, E. M. Pogliani, U. Vitolo, I. Kwee, F. Bertoni, A. Conconi, G. Gaidano posted to lymphoma pharmacogenetics by songpku on 2009-06-21 04:32:52 as
	DNA repair gene polymorphisms affect cytotoxicity in the National Cancer Institute Human Tumour Cell Line Screening Panel. [My Copy] Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, Vol. 10, No. 2-3. (n 2005), pp. 188-202. by D. B. Yarosh, A. Peña, D. A. Brown posted to dna pharmacogenetics polymorphism repair toxicity by songpku on 2009-06-19 17:23:09 as
	Prognostic Significance of p53 and X-ray Repair Cross-complementing Group 1 Polymorphisms on Prostate-Specific Antigen Recurrence in Prostate Cancer Post Radical Prostatectomy [My Copy] Clin Cancer Res, Vol. 13, No. 22. (15 November 2007), pp. 6632-6638. by Shu-Pin Huang, Chao-Yuan Huang, Jyh-Seng Wang, et al.Chia-Chu Liu, Yeong-Shiau Pu, Hong-Jeng Yu, Chia-Cheng Yu, Tony T. Wu, Chun-Hsiung Huang, Wen-Jeng Wu, Yii-Her Chou, Ming-Tsang Wu posted to cancer dna pharmacogenetics prognosis prostate repair by songpku on 2009-06-19 15:29:16 as
	XPD and XRCC1 Genetic Polymorphisms Are Prognostic Factors in Advanced Non--Small-Cell Lung Cancer Patients Treated With Platinum Chemotherapy [My Copy] J Clin Oncol, Vol. 22, No. 13. (1 July 2004), pp. 2594-2601. by Sarada Gurubhagavatula, Geoffrey Liu, Sohee Park, et al.Wei Zhou, Li Su, John C. Wain, Thomas J. Lynch, Donna S. Neuberg, David C. Christiani posted to cancer lung pharmacogenetics survival xpd xrcc1 by songpku on 2009-06-19 15:26:13 as
	DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy [My Copy] N Engl J Med, Vol. 355, No. 10. (7 September 2006), pp. 983-991. by Ken A. Olaussen, Ariane Dunant, Pierre Fouret, et al.Elisabeth Brambilla, Fabrice Andre, Vincent Haddad, Estelle Taranchon, Martin Filipits, Robert Pirker, Helmut H. Popper, Rolf Stahel, Laure Sabatier, Jean-Pierre Pignon, Thomas Tursz, Thierry Le Chevalier, Jean-Charles Soria, The posted to cancer ercc1 lung pharmacogenetics survival by songpku on 2009-06-19 15:25:05 as
	Pharmacogenetics of Oxazaphosphorines and its Clinical Implications [My Copy] Current Pharmacogenomics, Vol. 5, No. 2. (June 2007), pp. 143-156. by Zhou, Shu-Feng, Chowbay, Balram, Changli Xue, Charlie posted to cyclophosphamide pharmacogenetics review by songpku on 2009-06-15 16:26:02 as
	The role of genetic variability in drug metabolism pathways in breast cancer prognosis. [My Copy] Pharmacogenomics, Vol. 7, No. 4. (June 2006), pp. 613-624. by J. Y. Choi, S. A. Nowell, J. G. Blanco, C. B. Ambrosone posted to ambrosone breast cancer drug metabolism pharmacogenetics review by songpku on 2009-06-11 19:24:33 as along with 1 person misonneh

Note: You may cite this page as: http://www.citeulike.org/user/songpku/tag/pharmacogenetics

Result page: 1 2 Next

cancer	291
breast	205
polymorphism	101
pharmacogenetics	70
d	66
vitamin	66
microrna	62
dna	58
genetic	57
review	46
repair	45
mirna	43
disparity	35
racial	35
survival	34
toxicity	28
african	27
expression	27
cyclophosphamide	25
prostate	23
damage	21
estrogen	20
dcis	19
gene	19
stress	18
american	17
lung	16
oxidative	15
prognosis	14
sex	14
gstp1	13
cyp3a4	12
pigmentation	12
tamoxifen	12
hormone	11
mnsod	11
variation	11
vdr	11
cyp2b6	10
fancd2	10
variant	10
age	9
ambrosone	9
carcinoma	9
gsta1	9
gwas	9
metastasis	9
onset	9
snp	9
steroid	9
admixture	8
brca	8
colorectal	8
deficiency	8
drug	8
ductal	8
er	8
in	8
metabolism	8
of	8
situ	8
skin	8
subtype	8
taxane	8
tumor	8
bone	7
evolution	7
microarray	7
receptor	7
risk	7
sod	7
status	7
analysis	6
biology	6
cell	6
lymphoma	6
methylation	6
negative	6
pregnancy	6
signature	6
smoking	6
trial	6
women	6
chemotherapy	5
difference	5
excision	5
immune	5
interaction	5
interstrand	5
loss	5
meta-analysis	5
resistance	5
treatment	5
ancestry	4
cnv	4
doxorubicin	4
fgfr2	4
genotype	4
giovannucci	4
history	4
informative	4
marker	4
mdr1	4
menopausal	4
methotrexate	4
molecular	4
nadph	4
nucleotide	4
pharmacogenetic	4
postmenopausal	4
prevention	4
progression	4
variability	4
5-fluorouracil	3
abcb1	3
adriamycin	3
aim	3
alkylating	3
anthracycline	3
brca1	3
calcium	3
clinical	3
cross-link	3
cyp	3
cyp2d6	3
disease	3
early	3
epigenetic	3
factor	3
genotyping	3
germline	3
intolerance	3
lactose	3
let-7	3
mammary	3
method	3
modification	3
nhanes	3
non-smoker	3
obesity	3
osteoporosis	3
p450	3
paclitaxel	3
phenotype	3
radiotherapy	3
recurrence	3
sipa	3
somatic-mutation	3
statistical	3
stem	3
supplementation	3
triple	3
wchs	3
xrcc1	3
young	3
25-ohd	2
5-fu	2
activity	2
agent	2
androgen	2
aromatase	2
basal-like	2
biomarker	2
bmd	2
bwhs	2
component	2
crosslink	2
cyp1a1	2
cyp27b1	2
cytokine	2
cytotoxicity	2
data	2
database	2
development	2
diet	2
dietary	2
ercc1	2
esophageal	2
estradiol	2
etiology	2
ffpe	2
foxp3	2
function	2
genetics	2
glioblastoma	2
her2	2
heterogeneity	2
histone	2
igf-1	2
ihc	2
incidence	2
inflammation	2
invasive	2
mammography	2
mammorgraphy	2
matp	2
mcf-7	2
mgmt	2
mortality	2
natural	2
non-genetic	2
ovarian	2
pancreatic	2
panel	2
pathway	2
pattern	2
physical	2
phytoestrogen	2
polymorphis	2
pooled	2
pre-microrna	2
principal	2
promoter	2
pyschological	2
recommbination	2
reproductive	2
ses	2
somatic	2
stage	2
susceptibility	2
swog	2
therapy	2
tissue	2
topoisomerase	2
vitamind	2
vogelstein	2
whi	2
17q2131	1
abcg2	1
abuse	1
acid	1
africa	1
ageing	1
agents	1
aggressive	1
aging	1
alcohol	1
aldh1a1	1
allelic	1
allred	1
alpha	1
amplification	1
analaysis	1
and	1
antagomir	1
anticancer	1
apoptosis	1
array	1
asip	1
autopsy	1
base	1
base-excision	1
basic	1
behavioral	1
benefit	1
benign	1
beta	1
bile	1
bimodal	1
bioinformatics	1
birth	1
body	1
bone-a-fide	1
bph	1
break	1
breats	1
calgb	1
cancer-atlas	1
caner	1
canncer	1
capacity	1
carotene	1
catalase	1
cellular	1
children	1
cis	1
cohort	1
colon	1
color	1
common	1
complex	1
composition	1
contralateral	1
controlled	1
copy	1
cost	1
cox2	1
cps	1
crp	1
cyp17	1
cyp1a2	1
cyp1b1	1
cyp24a1	1
cyp2c19	1
cyp2c9	1
cyp3a5	1
cyp450	1
datashare	1
daunorubicin	1
dbbr	1
death	1
denosumab	1
density	1
determinants	1
diagnosis	1
dicer	1
disequilibrium	1
double	1
drosha	1
endocrine	1
energy	1
environment	1
environment-mediated	1
enzyme	1
epic	1
epigenetics	1
epirubicin	1
er-alpha	1
erbb2	1
estorgen	1
exercise	1
exposure	1
expresison	1
extraction	1
factors	1
familial	1
family	1
fancd	1
fat	1
feeding	1
functional	1
fusion	1
g6pd	1
g-csf	1
genome	1
genomic	1
geo	1
geographic	1
gland	1
gpx	1
grade	1
gwa	1
gxe	1
haplotype	1
heritability	1
homologous	1
hrt	1
human	1
hypoxic	1
i	1
iarc	1
igfbp2	1
ii	1
ile105val	1
image	1
immunity	1
immunomodulation	1
infection	1
informativeness	1
inheritance	1
inheritary	1
inheritation	1
inhibitor	1
insuline	1
intake	1
interindividual	1
intervention	1
intrauteral	1
involution	1
iwhs	1
johnson	1
klf17	1
lactase	1
lactation	1
late	1
leukemia	1
leukocytopenia	1
lifestyle	1
line	1
linkage	1
liver	1
location	1
low	1
macrophage	1
maligancy	1
mammographic	1
mapping	1
markers	1
matabolomics	1
maternal	1
mcf10	1
mdm2	1
mdr	1
measurement	1
menarche	1
metastatic	1
methotraxate	1
mice	1
micoran	1
micorrna	1
micrna	1
microenvironment	1
micro-environment	1
mining	1
mir-24	1
mircorna	1
mirna-200	1
modifiable	1
more	1
mpo	1
mthfr	1
mutation	1
neuropathy	1
neuroun	1
neutropenia	1
nhnesiii	1
nigerian	1
nih	1
node	1
nos	1
nqo1	1
nsaid	1
number	1
nutrition	1
oncomine	1
oncomir	1
opg	1
osteporosis	1
out	1
outcome	1
overexpression	1
p53	1
paraffin-embedded	1
parity	1
patrocles	1
pcpt	1
petabyte	1
phamacogenetics	1
phamarcogenetics	1
pharamacogenetics	1
pharmacoepigenetics	1
pharmacoethnicity	1
pharmacogenomics	1
pharmacokinetics	1
phase	1
plco	1
polarity	1
polygene	1
polymirts	1
polymophirsm	1
polymorphisms	1
polymrophism	1
polyrmophism	1
polysomy	1
population	1
positive	1
postmenopause	1
pr	1
predictor	1
premenopausal	1
pre-mirna	1
prevelance	1
primary	1
pri-mirna	1
project	1
prostaglandin	1
pxr	1
randomized	1
rankl	1
redox	1
regression	1
regulatory	1
reliability	1
renal	1
report	1
residual	1
resistanace	1
resistence	1
response	1
resting	1
retardation	1
reversion	1
rickets	1
rirna	1
rna	1
science	1
score	1
screening	1
scribble	1
second	1
selection	1
sequence	1
serum	1
signaling	1
silencing	1
size	1
slc24a5	1
small	1
snps	1
socialeconomic	1
socioeconomic	1
sod2	1
sod3	1
software	1
storage	1
strand	1
stromal	1
structural	1
structure	1
study	1
subtypes	1
sufficiency	1
sun	1
survical	1
survivor	1
synonymous	1
t	1
tagsnp	1
t-cell	1
testosterone	1
than	1
tissue-specifici	1
tmprss2egr	1
tool	1
trail	1
training	1
traits	1
transcriptomic	1
transition	1
transplantation	1
transporter	1
trump	1
vitmamin	1
wiki	1
wikigenes	1
workshop	1
wu	1
xenoestrogen	1
xifeng	1
xpd	1

songpku's pharmacogenetics [70 articles] Export

songpku's tags